The estimated Net Worth of Fabrice Egros is at least $468 Mille dollars as of 18 November 2021. Fabrice Egros owns over 14,030 units of Syndax Pharmaceuticals Inc stock worth over $293,670 and over the last 8 years he sold SNDX stock worth over $0. In addition, he makes $174,246 as Independent Director at Syndax Pharmaceuticals Inc.
Fabrice has made over 4 trades of the Syndax Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 14,030 units of SNDX stock worth $125,288 on 18 November 2021.
The largest trade he's ever made was exercising 15,635 units of Syndax Pharmaceuticals Inc stock on 18 August 2021 worth over $123,204. On average, Fabrice trades about 4,460 units every 22 days since 2016. As of 18 November 2021 he still owns at least 16,030 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Fabrice Egros stock trades at the bottom of the page.
Dr. Fabrice Egros Ph.D. serves as Independent Director of the Company. Since October 2015, Dr. Egros has served as President, Asia Pacific and Japan of Lupin Limited, an Indian publicly traded pharmaceutical company. From November 2012 to September 2015, Dr. Egros served as the Deputy Chief Executive Officer/Chief Operating Officer of NovaMedica LLC, a privately held pharmaceutical company, and was its Chief Operating Officer and a member of its board of directors from July 2012 to September 2015. From February 2011 to July 2012, Dr. Egros served as the Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., a privately held pharmaceutical company. From September 2009 to February 2011, he served as the Senior Vice President, Corporate Business Development and Strategy of UCB, S.A., a publicly traded biopharmaceutical company. Prior to that, Dr. Egros served as the President of UCB, Inc. and of UCB Japan Co. Ltd., each a subsidiary of UCB, S.A. Prior to joining UCB, Dr. Egros held various management and executive positions at Parke-Davis, Warner Lambert Company, a privately held pharmaceutical company, and Sanofi, formerly known as Sanofi-Aventis, a publicly traded pharmaceutical company. Dr. Egros received a B.S. in Pharmacokinetics and Metabolism and a Pharm.D. and Ph.D. in Pharmaceutical Sciences from Chatenay Malabry University, and has participated in the Advanced Management Program at Harvard University. He also holds an MBA from Schiller International University. Egros’ experience as an executive officer of other successful companies in the pharmaceutical industry gives him the qualifications, skills and financial expertise to serve on our board of directors.
As the Independent Director of Syndax Pharmaceuticals Inc, the total compensation of Fabrice Egros at Syndax Pharmaceuticals Inc is $174,246. There are 8 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.
Fabrice Egros is 58, he's been the Independent Director of Syndax Pharmaceuticals Inc since 2013. There are 7 older and 10 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.
Fabrice's mailing address filed with the SEC is C/O SYNDAX PHARMACEUTICALS, INC., 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451.
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin e Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include: